Sandeep Chhabra

Sandeep Chhabra

Auto-generated profile, based on publicly available information

Sandeep Chhabra

Cancer Biology Dana-Farber Cancer Institute 450 Brookline Avenue LC-3311 Boston MA 02215 USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JDJiehui Deng
Jiehui Deng
EWEric S. Wang
Eric S. Wang
RJRussell W. Jenkins
Russell W. Jenkins
SLShuai Li
Shuai Li
RDRuben Dries
Ruben Dries
KWKwok-Kin Wong
Kwok-Kin Wong
Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the efficacy of existing immunotherapies, we screened for small molecules capable of increasing the activity of T cells suppressed by PD-1. Here, we show that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) significantly enhances T-cell activation, contributing to antitumor effects in vivo, due in part to the derepression of NFAT family proteins and their target genes, critical regulators of T-cell function. Although CDK4/6 inhibitors decrease T-cell proliferation, they increase tumor infiltration and activation of effector T cells. Moreover, CDK4/6 inhibition augments the response to PD-1 blockade in a novel ex vivo organotypic tumor spheroid culture system and in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. Significance: Our results define previously unrecognized immunomodulatory functions of CDK4/6 and suggest that combining CDK4/6 inhibitors with immune checkpoint blockade may increase treatment efficacy in patients. Furthermore, our study highlights the critical importance of identifying complementary strategies to improve the efficacy of immunotherapy for patients with cancer. Cancer Discov; 8(2); 216–33. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Jenkins et al., p. 196. This article is highlighted in the In This Issue feature, p. 127

11 March 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
ABAndras Boeszoermenyi
Andras Boeszoermenyi
SCSandeep Chhabra
Sandeep Chhabra
Abhinav DubeyAbhinav Dubey
Abhinav Dubey
DRDenitsa L. Radeva
Denitsa L. Radeva
NBNikola Burdzhiev
Nikola Burdzhiev
HAHaribabu Arthanari
Haribabu Arthanari

31 August 2011 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
BGBim Graham
Bim Graham
CLChoy Theng Loh
Choy Theng Loh
JSJames David Swarbrick
James David Swarbrick
PUPhuc Ung
Phuc Ung
JSJames Shin
James Shin
GOGottfried Otting
Gottfried Otting

2 June 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SCSandeep Chhabra
Sandeep Chhabra
SCShih Chieh Chang
Shih Chieh Chang
HNHai M. Nguyen
Hai M. Nguyen
RHRedwan Huq
Redwan Huq
MTMark R. Tanner
Mark R. Tanner
KCK. George Chandy
K. George Chandy
The voltage‐gated potassium (Kv) 1.3 channel is widely regarded as a therapeutic target for immunomodulation in autoimmune diseases. ShK‐186, a selective inhibitor of Kv1.3 channels, ameliorates autoimmune diseases in rodent models, and human phase 1 trials of this agent in healthy volunteers have been completed. In this study, we identified and characterized a large family of Stichodactyla helianthus toxin (ShK)‐related peptides in parasitic worms. Based on phylogenetic analysis, 2 worm peptides were selected for study: AcK1, a 51‐residue peptide expressed in the anterior secretory glands of the dog‐infecting hookworm Ancylostoma caninum and the human‐infecting hookworm Ancylostoma ceylanicum , and BmK1, the C‐terminal domain of a metalloprotease from the filarial worm Brugia malayi. These peptides in solution adopt helical structures closely resembling that of ShK. At doses in the nanomolar‐micromolar range, they block native Kv1.3 in human T cells and cloned Kv1.3 stably expressed in L929 mouse fibroblasts. They preferentially suppress the proliferation of rat CCR7 ‐ effector memory T cells without affecting naive and central memory subsets and inhibit the delayed‐type hypersensitivity (DTH) response caused by skin‐homing effector memory T cells in rats. Further, they suppress IFNγ production by human T lymphocytes. ShK‐related peptides in parasitic worms may contribute to the potential beneficial effects of probiotic parasitic worm therapy in human autoimmune diseases.—Chhabra, S., Chang, S. C., Nguyen, H. M., Huq, R., Tanner, M. R., Londono, L. M., Estrada, R., Dhawan, V., Chauhan, S., Upadhyay, S. K., Gindin, M., Hotez, P. J., Valenzuela, J. G., Mohanty, B., Swarbrick, J. D., Wulff, H., Iadonato, S. P., Gutman, G. A., Beeton, C., Pennington, M. W., Norton, R. S., Chandy, K. G. Kv1.3 channel‐blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 28, 3952‐3964 (2014). www.fasebj.org

28 March 2014 in Scientific Reports
Verified
Journal Article
Open access
MRM. Harunur Rashid
M. Harunur Rashid
RHRedwan Huq
Redwan Huq
MTMark R. Tanner
Mark R. Tanner
SCSandeep Chhabra
Sandeep Chhabra
KKKeith K. Khoo
Keith K. Khoo
Raymond NortonRaymond Norton
Raymond Norton
HsTX1 toxin, from the scorpion Heterometrus spinnifer, is a 34-residue, C-terminally amidated peptide cross-linked by four disulfide bridges. Here we describe new HsTX1 analogues with an Ala, Phe, Val or Abu substitution at position 14. Complexes of HsTX1 with the voltage-gated potassium channels Kv1.3 and Kv1.1 were created using docking and molecular dynamics simulations, then umbrella sampling simulations were performed to construct the potential of mean force (PMF) of the ligand and calculate the corresponding binding free energy for the most stable configuration. The PMF method predicted that the R14A mutation in HsTX1 would yield a > 2[emsp14]kcal/mol gain for the Kv1.3/Kv1.1 selectivity free energy relative to the wild-type peptide. Functional assays confirmed the predicted selectivity gain for HsTX1[lsqb]R14A[rsqb] and HsTX1[lsqb]R14Abu[rsqb], with an affinity for Kv1.3 in the low picomolar range and a selectivity of more than 2,000-fold for Kv1.3 over Kv1.1. This remarkable potency and selectivity for Kv1.3, which is significantly up-regulated in activated effector memory cells in humans, suggest that these analogues represent valuable leads in the development of therapeutics for autoimmune diseases.

24 May 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JSJames D. Swarbrick
James D. Swarbrick
DSDaniel J. Shaw
Daniel J. Shaw
SCSandeep Chhabra
Sandeep Chhabra
RGRajesh Ghai
Rajesh Ghai
EVEugene Valkov
Eugene Valkov
BCBrett M. Collins
Brett M. Collins
VPS29 is a key component of the cargo-binding core complex of retromer, a protein assembly with diverse roles in transport of receptors within the endosomal system. VPS29 has a fold related to metal-binding phosphatases and mediates interactions between retromer and other regulatory proteins. In this study we examine the functional interactions of mammalian VPS29, using X-ray crystallography and NMR spectroscopy. We find that although VPS29 can coordinate metal ions Mn2+ and Zn2+ in both the putative active site and at other locations, the affinity for metals is low, and lack of activity in phosphatase assays using a putative peptide substrate support the conclusion that VPS29 is not a functional metalloenzyme. There is evidence that structural elements of VPS29 critical for binding the retromer subunit VPS35 may undergo both metal-dependent and independent conformational changes regulating complex formation, however studies using ITC and NMR residual dipolar coupling (RDC) measurements show that this is not the case. Finally, NMR chemical shift mapping indicates that VPS29 is able to associate with SNX1 via a conserved hydrophobic surface, but with a low affinity that suggests additional interactions will be required to stabilise the complex in vivo. Our conclusion is that VPS29 is a metal ion-independent, rigid scaffolding domain, which is essential but not sufficient for incorporation of retromer into functional endosomal transport assemblies.